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Abstract. Studies on human osteoclast formation have
been hampered by lack of a defined isolated progenitor
cell population. We describe here the establishment
of a human leukemic cell line (designated FLG 29.1)
from bone marrow of a patient with acute monoblastic
leukemia. The cultured cells are predominantly undif-
ferentiated leukemic blasts, but addition of 12-o-tetra-
decanoylphorbol 13-acetate (TPA; 0.1 p,M) induces ir-
reversible differentiation into adherent, non-dividing,
multinucleated cells. TPA-treated cells bear surface an-
tigens typical of fetal osteoclasts, degrade 45Ca-labeled
T
HERE is an ample evidence that the osteoclast, the
cell that resorbs bone, is derived from some precursor
cell carried with the blood vascular system (45). How-
ever, the precise nature of the immediate osteoclast precursor
is still unknown. Initially it was believed that circulating
monocytes were osteoclast precursors for their ability offus-
ing in multinucleated cells (65). It was later established that
tissue macrophages and monocytes isolated from the circula-
tion significantly differ from osteoclasts in morphology, anti-
genic properties, and bone resorbing activity (17, 29, 30, 63).
It was then proposed that the osteoclast originates from an
early precursor common to the monocytic and granulocytic
lineages (12) .
Recovery of a definitive homogeneous osteoclast popula-
tion from bone tissue has not yet been achieved. Studies in
this area generally have used preexisting cells stripped from
growing bones (27, 50). Such models, however, do not per-
mit analysis ofthe sequential steps in differentiation from the
precursor to the mature cell. Moreover, cell viability is often
poor. In contrast, purification of precursor subpopulations
has allowed studies on osteoclast maturation in vitro (12,
32) . These progenitor cells fuse spontaneously as well as in
response to a variety of agents, including osteotropic hor-
mones (43), transforming growth factors (51, 66), and bone
matrix constituents (36, 44, 56). These precursors, however,
are not readily identifiable and their features may vary from
preparation to preparation. Another approach has used hu-
man leukemic cell lines, such as HL60 and U937 cells, in-
duced by TPA and 1,25 dihydroxyvitamin D3 (1,25(OH)2D3)
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devitalized bone particles, display tartrate-resistant
acid phosphatase in both mononuclear and multinuclear
cells and receptors for calcitonin . Calcitonin increases
intracellular cAMP accumulation in TPAtreated cells.
TPA-treated cells show some ultrastructural features
of osteoclasts as evidenced by transmission EM . These
results indicate that FLG 29.1 cells may represent an
osteoclast committed cell population, which upon in-
duction with TPA acquire some morphological, pheno-
typical, and functional features of differentiated osteo-
clasts.
to differentiate toward monocyte macrophages and which
might show some resorbing activity in vitro (7, 28, 59) .
These in vitro-derived macrophage-like cells considerably
differ, however, from osteoclasts both functionally and phe-
notypically. The development of a clonal population of os-
teoclast precursors would offer a unique tool for studying
mechanisms that regulate replication and differentiation of
osteoclasts. The use of pure populations of progenitors and
terminally differentiated osteoclasts would further allowthe
analysis of interactions between homogeneous, but distinct
classes of bone cells.
We report here the development of a human leukemic cell
line, designated FLG 29.1, that can be induced to differenti-
ate in vitro towards the osteoclastic phenotype.
Materials and Methods
Culture Conditions, Cytochemical, Biochemical, and
UltrastructuralStudies
FLG 29.1 cell line was established at the U.O. Hematology of Florence
(USL 10/D) from a 38-yr-old female suffering from acute monoblastic
leukemia, M5a type according to the FAB classification (9). The clinical
course ofthis patient was characterized, after a 15 mo complete remission,
by a fatal pancytopenic episode associated with a peripheral neuropathic
syndrome and generalized increase in bone density. Bone marrow
mononuclear cells were isolated on Ficoll-Hypaque gradient (Pharmacia,
Uppsala, Sweden) and resuspended in RPMI4640 culture medium (Flow
laboratories Inc., Irvine, UK) supplemented with 10% heath inactivated
FCS. Cells (105 cells/ml) were grown in Falcon polystyrene tissue culture
flasks at 37°C in atmosphere of 5% C02/95% air. An adherent cell
437monolayer developed after 20 d ofculture and on top of the adherent cells
a homogeneous population of floating cells proliferated. This latter cell
population was collected, propagated in suspension culture and cloned by
limiting dilution. The cell line was determined to be free of mycoplasma
contamination and has been maintained in continuous suspension culture
for almost 4 yr. HL60 and U937 human leukemic cell lines were obtained
by ATCC and grown in RPMI-1640 medium supplemented with 10% heat-
inactivated FCS. TPA (Sigma Chemical Co., St. Louis, MO) was solubi-
lized in acetone at 0.16 mM. Cell differentiation was obtained by adding
TPA to the cell suspension at a final concentration of 0.1 uM for 72 h of
culture. Control cultures contained equal amounts of acetone. 1,25 Di-
hydroxyvitamin D3 (Hoffman-La Roche) was dissolved in absolute ethanol
at 1 mM and diluted into culture medium at a final concentration of 10 nM
for induction experiments (72 h in the dark). For cooperation experiments
1,25(OH)2D3 was added to FLG 29.1 cell cultures after 12-h preincubation
with 0.1 AM TPA and then the incubation proceeded for the remaining 60 h
in the dark. Control cultures contained equal amounts of acetone and
ethanol.
Daily cell counts were performed with a Coulter Counter to assess
growth kinetics. Viability was evaluated by trypan blue exclusion. Upon
treatment with 0.1 uM TPA for 72 h cell adhesion was calculated on the
total number ofviable cells. The ability of FLG 29.1 cells to formcolonies
in soft agar was assessed by plating them in 35-mm Petri dishes in 1 ml of
RPMI-1640 medium containing 20% FCS and 0.3% agar (Bactoagar;
Difco, Detroit, MI). De novo synthesis of DNA was assessed by a standard
[3H]thymidine incorporation microassay (60). Cells were assessed mor-
phologically on cytospin slide preparations stained with May-Grunwald-
Giemsa, Sudan Black, PAS, acid phosphatase and tartrate-resistant acid
phosphatase (TRAPase), naphtol ASD chloroacetate esterase, and sodium
fluoride inhibitable a-naphthyl acetate esterase (19). TRAPase activity in
the whole cell population was measured using p-nitrophenylphosphate as
substrate as previously described and expressed as MIU/106 cells (41). In-
tracellular and extracellular tissue plasminogen activator antigen (tPA) was
measured by using a highly specific two-site immunoassay (Biopool AB,
Umea, Sweden) (55). For the evaluation ofthe cellular content ofTRAPase
and tPA the cells were extracted for 10 min with HBSS buffer containing
1% Nonidet. Phagocyticactivity was measured with a flow cytometry tech-
nique that discriminates between internalized and membrane-bound
fluorescein-conjugated heat-killed Candida albicans (24). Generation ofsu-
peroxide was measured in FLG 29.1 cells by the ability to reduce nitroblue
tetrazolium (NBT) in intracellular blue-black formazan deposits (34). FLG
29.1 cells were analyzed by transmission EM after 72 h of culture with or
without 0.1 uM TPA. In separate experiments TPA-treated FLG 29.1 cells
were also co-cultured with dentine slices. Both suspended and adherent
cells were centrifuged at 800 g and the pellet obtained was fixed in4% cold
glutaraldehyde in 0.1 M cacodylate buffer at pH 7.4, at room temperature
for 1 h and postfixed in 1% OsO4 in 0.1 M phosphate buffer, pH 7.4, at 4°C
for 1 h. The pellets were then dehydrated and embedded in Epon 812. Semi-
thin sections were used for light microscopy observation. From the same
specimens ultrathin sections were also obtained and stained with uranyl
acetate and alkaline bismuth subnitrate for EM.
KaryotypeAnalysis
Cells after the 20th and 150th passage were treated with Colcemid for 30
minandthen with0.075 M KCl for 20 min. The preparations were then har-
vested and fixed in methanol/acetic acid (3:1, vol/vol). Metaphases were
stained to obtain GTG and RHA banding (21, 62).
Molecular Rearrangements and Epstein-Bare
Virus Detection
Immunoglobulin genes and T cell receptor status in genomic DNA ex-
tracted from FLG 29.1 cells were analyzed by probing Southern blots with
multiprime-labeled DNA fragments specific for itnmunoglobulin-JH and
-C-,u and T cell receptor-0 and -r constant regions as described (14). Cells
were also tested for Epstein-Bare virus DNA (53).
1. Abbreviationsusedin thispaper: APAAP, alkaline phosphataseanti-alka-
line phosphatase; H-CAM, homing-associated cell adhesion molecule;
I-CAM, intercellular adhesion molecule; MHC, major histocompatibility
complex; NBT, nitroblue tetrazolium; TRAPase, tartrate-resistant acid
phosphatase; TPA, 12-o-tetradecanoylphorbol 13-acetate; tPA, tissue plas-
minogen activator.
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Immunological Characterization
The cell surface antigenic pattern was analyzed with a standard im-
munofluorescence method using a FACStar cytofluorograph (Becton Dick-
inson and Co., Itnmunocytometry Systems, Mountain View, CA) as previ-
ously described (52). Cytoplasmic antigens were detected with a standard
alkaline phosphatase anti-alkaline phosphatase (APAAP) immunoen-
zymatic procedure (14). Most mAbs used derived from the panels of the
IIIrd and IVth editions of the International Conference and Workshop on
Leukocyte Antigens (39, 40). Other mAbs were purchased from Ortho
(Raritan, NJ), Coulter (Coulter Immunology, Hieleah, FL), Becton Dickin-
son (Sunnyvale, CA), and Dako (Dakopattz, Glastrup, Denmark).
Western Blotting
The crude membrane fraction of untreated and TPA-treated (0.1 14M for
72 h) were solubilized in SDS sample buffer (0.125 M Tris-HCl, pH 6.8,
2 % SDS, and 10% glycerol) overnight at room temperature (38). The solu-
bilized membrane fraction was subjected to SDS-gel electrophoresis on
10% polyacrylamide gels and then transferred electronically to nitrocellu-
lose withtransferbuffer(20mM Trisbase, 150 mM glycine, and20% meth-
anol) overnight at 4°C (13). The protein bands were blocked with HBSS
buffer containing 3 % BSA and0.1% Tween-20overnightat 37°C. The trans-
ferred proteins were then reacted with mAb Kn22 (35) in the presence of
1% horseserum and 0.01% Tween-2030 minat room temperature. The pro-
tein bands were detected by Vectastain ABC-AP kits.
Bone Resorption
Resorption ofdevitalized bone by FLG 29.1 and HL60 cells was quantified
using particles of e5Ca-labeled bone as described by Teitelbaum et al. (69) .
Devitalized rat bone particles ('Ca labeled, 45-50-uM diam) were added
to the FLG 29.1 and HL60 cells cultured in 16-mm wells (106 cells/well)
in RPMI-1640 medium containing 10% FCS in the presence or in the ab-
sence of 0.1 uM TPA. After 72 h incubation the upper one-half of the
medium was aspirated, centrifuged at 15,000 g, and assayed for radiocal-
cium. The pellet and remaining halfofthe incubation medium were solubi-
lized in 10% TCA for 24 h and assayed. Net 45Ca release was calculated
from the isotope released into the medium expressed as percent of total,
after correction for the loss ofisotope from the particles because of simple
physicochemical exchange with 45Ca. To assess whether any resorption
might be potentially due to release of lytic enzymes from cells, similar ex-
periments were carried out with conditioned media obtained from 3-d-old
cultures.
Formation of resorption lacunae on dentine slices was evaluated using
sperm whale dentine slices kindly supplied by Dr. A. Boyde (University
College, London, UK). FLG 29.1 cells were co-cultured with the dentine
slices plated in 16-mm wells (106 cells/well) in 10% FCS RPMI-1640
medium to which 0.1 uM TPA had been previously added. 72-h later the
cells were washed twice with RPMI-1640 medium supplemented with 10%
FCS and co-cultures were incubated forup to 20 d ingrowth medium. Den-
tine slices were processed as previously described (10, 33) forscanning EM .
cAMPAccumulation
Intracellular CAMP content in FLG 29.1, HL60 and U937 cells was mea-
sured by radioimmunoassay. Untreated cells were washed with cold HBSS,
suspended in assay buffer (TRIS acetate 0.025 M buffer, pH 7.4, containing
0.25 M sucrose, 0.5% BSA, and 3-isobutyl-l-methylxanthine) and trans-
ferred to test tubes (105 cells/tube). Differentiated cells were plated in 16-
mm wells at a concentration of 105 cells per well and cultured for 72 h in
growth medium containing 0.1 AM TPA. Then the medium was carefully
aspirated, adherent cells gently washed with cold HBSS, and assay buffer
added. Quadruplicate samples of untreated or TPAtreated FLG 29.1 cells
were incubated with 1 pM to 0.1 uM salmon CT (Sandoz Pharma, Basel,
Switzerland) for 30 min, whileTPA-induced HL60 and U937 cells were ex-
posed to 1 nM dose of salmon CT for 30 min. Cells were then washed with
cold HBSS, and covered withabsolute ethanol overnight at -20°C. The eth-
anol was removed under vacuum and samples reconstituted with0.05 M so-
dium acetate buffer, pH 6.2. CAMP was determined by radioinununoassay
as previously described (11).
Immunocytochemical evaluationofcyclic AMP was carried out as previ-
ously described (8). Both untreated and TPAtreated (0.1 uM for72 h) FLG
29.1 cells were incubated for 30 min at 37°C with or without 1 nM salmon
CT in CAMP assay buffer and cytospin slide preparations were then ob-
438tained . Immunostaining was performed with the APAAP method as de-
scribed (8) .
Calcitonin BindingStudies
FLG 29.1 cells differentiated with 0.1 AM TPA for 72 h were transferred
to test tubes (106 cells/tube) and incubated for 120 min with increasing
concentrations (0.1-1.0 nM) of 1251-labeled salmon CT (sp act. 2,200
Ci/mmol, Anawa Laboratorien AG, Wangen, Switzerland) with or without
unlabeled salmon CT (0.1 mM) at 22°C in binding buffer containing 100
mM Hepes, 1mM EDTA, 10mM glucose, 15mM sodium acetate, 1 .3mM
MgSO4, 5 mM KCI, 120 mM NaCl, and 1% BSA, pH 7 .6 . After incuba-
tion samples were washed with HBSS containing 1% BSA and centrifuged.
Cell pellets were then counted in a gamma counter at 70% efficiency. All
experiments were carried out in triplicate. Scatchard analysis of binding
data from three experiments was performed using the computer program
LIGAND (47) .
Quantitative Histomorphometry
FLG 29.1 cells were cultured with 0.1 AM TPA for 72 h . Cells were then
washed with RPMI-1640 mediumand treatedwith 1 nM salmon CT for 3 h
at 37°C . Phase contrast micrographs were taken before and after the addi-
tion of salmon CT. Plan areas of 100-150 FLG 29 .1 cells were measured
on the enlarged micrographs using a computer program equipped with a
NIKON Cosmozone .
StatisticalAnalysis
Results were evaluated statistically by t test .
Results
Growth Characteristics
UntreatedFLG 29.1 cells grew as small floating clumps with
a doubling time in the logarithmic phase of ti 22 h . The cells
produced a population of colonies in semisolid agar directly
related to thenumberof cells plated, with a plating efficiency
of -40% . TPA (0.1 /AM) caused an irreversible decrease in
[ 3H]thymidine incorporation with growth arrest in liquid or
semisolid medium (data not shown) . Trypan blue exclusion,
indicated <5% positive cells after TPA treatment .
Karyotype andMolecularAnalysis
The FLG 29 .1 cell karyotype showed numbers of chromo-
somes ranging from 45 to 69 with constant expression of the
3p+ marker. Southern blot analysis showed no detectable
Epstein-Barr virus in DNA from FLG 29.1 cells and main-
tenance ofagerm line configuration ofJH and C-1, immuno-
globulin regions and of T cell receptor-ß and -r genes .
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Morphology, Cytochemistry and Ultrastructure
FLG 29 .1 cells stained with May-Grunwald-Giemsa ap-
peared like undifferentiated leukemic blasts, with large
round nuclei, prominent nucleoli, dispersed nuclear chro-
matin and basophilic cytoplasm . The diameter of the cells
ranged from 15 to 20 p,m (Fig. 1 a) . Less than 3% ofthe cells
were multinucleated, and commensurately larger in dimen-
sions . Only a minority of the untreated cells adhered to the
plastic surface . After 72 h of treatment with 0.1 p,M TPA,
36% of the cells were attached to the substrate and >45
multinucleated (3 to 12 nuclei) with size ranging from 50 to
100 jm (Fig . 1, b and c) . Multinucleated cells were found
attached or in suspension and lacked characteristic periph-
eral ruffling. Fluorochrome-conjugated Candida particles
were not internalized by both untreated and TPAinduced
FLG 29.1 cells . No detectable tPA was found in either the
conditioned medium or the cytosol of untreated FLG 29 .1
cells . After treatment ofFLG 29.1 cells with 0.1 uM TPA for
72 h the levels of tPA in the conditioned medium and inside
the cells were respectively 0.57 f 0.08 ng/106 cells and
1.29 t 0.33/10 6 cells . Untreated FLG 29.1 cells did not
stain with Sudan Black, naphtol ASD-chloroacetate esterase
and PAS reaction, while acid phosphatase and sodium fluo-
ride inhibitable a-naphthyl acetate esterase were present in
100% of the cells with 10 t 2% of TRAPase-positive cells .
TPA (0.1 IAM for 72 h) treatment increased by 48 f 6% the
number ofcells positive for TRAPase, the TRAPase content
of the total population of cells (4.2 t 0.6 MIU/106 cells vs
1.4 t 0.4 mIU/106 cells), the production of acid phospha-
tase, and sodium fluoride inhibitable a-naphthyl acetate es-
terase . NBT was reduced by cellular oxidants to formazan in
21 f 5% of untreated FLG 29.1 cells . The number of cells
able to accumulate formazan increased to 85 f 8% in TPA-
induced FLG 29 .1 cells . Expression ofTRAPase and other
enzymes did not correlate with adherence or multinucle-
ation .
Transmission EM showed that most of the untreated cells
had cytoplasmic features of undifferentiated blasts, namely
abundant free ribosomes, scarce organelles, large and ir-
regularly shaped nucleus with dispersed chromatin and large
nucleoli (Fig . 2 a) . Rare cells with multiple nuclei were ob-
served . After treatment with 0 .1 p,M TPA for 72 h FLG 29.1
cells appeared to be in a more advanced stage of differentia-
tion, containing rather numerous rod-shaped mitochondria
and a well developed RER (Fig. 2 b), large Golgi areas
Figure 1. Light microscopy ofFLG29.1 cells . (a) Untreated cells ; (band c) cells treated with 0.1 AMTPA for 72 h (May-Grunwald-Giemsa) .
Bar, 20 Am .
439Figure 2 . (a) Untreated FLG 29.1 cells . The cytoplasm shows scarce organelles apart numerous free ribosomes; the nucleus is large and
irregularly-shaped with dispersedchromatin . (b) TPA-treatedFLG 29 .1 cells . Thecytoplasm reveals abundantRERand several rod-shaped
mitochondria . Bar, 2 um .
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440Figure 3. TPA-treated FLG 29.1 cells . (a) Multiple Golgi areas and (b) several lysosomes can be seen . Bars : 1 1m .
(Fig . 3 a), and several dense bodies resembling lysosomes
(Fig . 3 b) .
ImmunophenotypicalAnalysis
Table I summarizes the immunophenotypical characteriza-
tion of untreated and TPA-treatedFLG 29 .1 cells . Cells were
negative for mature and immature T cell (CDla, CD2, CD3,
CD5, CD7, CD8) and B cell (CD19, CD20, CD21, CD22,
CD23, CD24) restricted markers and for anti-CD25 mAb
recognizing IL2 membrane receptor, a molecule expressed
by activated macrophages, B and T cells. In addition, other
mAbs recognizing multilineage hemopoietic precursors (anti-
CD33, CD34), myelo-monocytic antigens (CD11a, c, CD14,
CD16, CD18, CD35, CD36), certain platelet-associated anti-
gens (CD41, Factor VIII-Related Antigen, PLTI), and class
II antigens ofthe major histocompatibility complex (MHC)
(HLA-DR, -DP, and -DQ) showed little (<20% positive
cells) or no reactivity with either uninduced or TPA-treated
cells . TPA-untreated cells showed a low reactivity for MHC
class I determinants (expressed only after TPA induction),
displayed CD71/transferren receptors (down regulated by
TPA treatment), and reacted strongly with the panleukocyte
mAbs anti-CD45, anti-CD44 (homing-associated cell adhe-
sion molecule, H-CAM), along with other mAbs specifically
directed against determinants shared by activated macro-
phages and osteoclasts . This latter group includes anti-CD1lb,
anti-CD13, anti-CD15, anti-CD32, and anti-CD54 (intercel-
lular adhesion molecule/ICAM-1) mAbs . The anti-CD68
KiM6mAb showed a cytoplasmic positivity revealed via the
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APAAP method, which was increased after TPA exposure
(data not shown) . TPA-treatedFLG 29.1 cells also expressed
CD9 (common to osteoclasts and platelets) andCD42 (com-
mon to osteoclasts, macrophages, and platelets) antigens . Fi-
nally, antigens recognized by the two mAbs 13C2 and 23C6,
putatively specific for human osteoclasts (30), were signifi-
cantly induced by TPA treatment (Fig . 4) . Fluorescence his-
tograms for osteoclast-related antigens before and afterTPA
treatment were expressed as single peaks, thus excluding the
existence of heterogeneous cell subpopulations within the
clonalFLG 29 .1 cell line . The osteoclast-associated antigens
recognized by the 13C2 and 23C6 mAbs were also detected
by APAAP staining of TPA-induced FLG 29.1 cells (data not
shown) . It is of interest to point out that no significant differ-
ences in APAAP staining with 13C2 and 23C6 mAbs were
noted between mononuclear and multinucleated cells. Con-
versely, neither antigen was induced by TPA in the other leu-
kemic cell lines HL60 and U937 (Fig . 4) .
A crude membrane preparation of both untreated and
TPAtreated FLG 29.1 cells was prepared and subjected to
SDS-polyacrylamide gel electrophoresis and transferred to
nitrocellulose, and the protein band reactive with the mAb
Kn22 was identified . As shown in Fig . 5, a single band of
-50 kD was detected with mAb Kn22 only in TPA-treated
cells, while no bands were detected in untreated FLG 29.1
cells.
Bone Resorption
Untreated FLG 29.1 cells were inactive with 4-'Ca-labeled
44 1Table L Phenotypic Profile ofFLG 29.1 Cells before and after TPA Exposure and Its Relationship with Normal
Fetal Bone Osteoclasts
Abbreviations used: Macrophage polykaria, Macropoly; Thelper lymphocytes, Th; Macrophages, Macro; Myeloid cells, My; Monocytes, M; platelets, pit; dendrit-
ic reticulum cells, DRC; red blood cells, RBC; neutrophils, PMN; activated cells, Act; B lymphocytes, B; not tested, NT.
* According to the "IVth International Workshop and Conference on Human Leucocyte Differentiation Antigens" (alien, 1989) (28).
$ Data obtained from references 1-4, 22, 23, 32.
mAbs additionally tested and resulting negative, indicated as CD include: CDla, 2, 3, 5, 7, 8, 10, 16, 19, 20, 21, 22, 23, 24, 25, 30, 38, 56, 57, and Factor
VIII-related antigen.
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Figure 4. Reactivity of FLG 29.1 (0), HL60 (1), and U937 (N)
cells to 13C2 and 23C6 mAbs. Analyses were carried out in un-
treated cellsandaftertreatmentwith 0.1 pM TPA for72 h. Results
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devitalized bone particles; TPA-treated cells resorbed these
bone particles effectively (p < 0.005; Fig. 6). Neither unin-
duced nor TPA-inducedHL60 cells were active in this assay
(Fig. 6). 60% of the effect exertedby TPA-treated FLG 29.1
cells on 45Ca mobilization was due to factor(s) released into
the medium (Fig. 6) . Under similar experimental condi-
tions, no effect wasfoundwith conditioned mediafrom unin-
duced cells nor from untreated or TPA-treated HL60 cells
(Fig. 6) . Correcting mediapH to 7.4 dailywith Hepesor in-
creasing the C02 in the airup to 10% did not influence this
result (data not shown) .
Neither untreated nor TPA-treated FLG 29.1 cells caused
resorption of sperm whale dentine slices (data not shown) .
are expressed as percent of stained cells evaluated by quantitative
fluorescence analysis in flow cytometry. For details, see Materials
and Methods.
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FigureS . Identification of Kn22
antigen by Western blot . The
SDS-polyacrylamide gel of
the membrane fraction of un-
treated and TPA-treated FLG
29.1 cells, the protein transfer,
and the Western blotting with
themAb Kn22 were carriedout
as described in Materials and
Methods . The arrowhead indi-
cates a single band of-50kD
detected with Kn22 in TPA
treated FLG 29.1 cells . No re-
activity was seen with undif-
ferentiated FLG 29 .1 cells.
After 30-min incubation salmon CT from a concentration of
1 pM and 0.1 AM caused a slight, but no significant increase
in CAMP content of untreated FLG 29.1 cells (Fig . 7) . In
TPA-induced cells we found a dose-dependent increase in
CAMP response to sCT, with a maximal stimulatory effect
at 1 nM (p< 0.001) and a lower response at higher concentra-
tions (Fig. 7) . Conversely, TPA-induced HL60 and U937
cells did not respond to 1 nM salmon CT after 30-min incu-
bation (Fig . 8) .
Immunostaining ofboth differentiated and undifferentiated
FLG 29.1 cells incubated in assay buffer without salmon
CT showed very little CAMP signal near the plasma mem-
brane and also very little diffusely in the cytoplasm (data not
shown) . At 1-nM concentration for 30 min salmonCT caused
CAMP accumulation only in TPA-treated FLG 29.1 cells as
well in the cytoplasm and along the plasma membrane, with
no differences between mononuclear and multinucleated
cells (data not shown) .
CONTROL FLG 29.1
￿
HL60
￿
FLG 29.1
￿
HL60
SUPERNATANT ,
TPA - + - + - + - + - +
Figure 6. Role of cell-bone contact in FLG 29.1-induced bone re-
sorption . Control ( 0) refers to cultures which contained labeled
bone alone. FLG 29.1 cells (0) and HL60 cells (/) were cul-
tured for 72 h with prelabeled bone with and without 0.1 AM TPA .
Groups ofbone particles were incubated in cell-free wells contain-
ing conditioned media recovered from 3-d-old cultures . Six repli-
cate cultures were assessed foreach variable, as described inMaterials
and Methods .
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Figure 7 . CyclicAMP production by FLG 29.1 cells in response to
salmonCT. Quadruplicate untreated (o) and TPA-treated (e) FLG
29.1 cells were exposed to 0 .5 mM 3-isobutyl-l-methylxanthine and
increasing concentrations of salmon CT for 30 min . Cyclic AMP
was assayed as described in Materials and Methods .
Calcitonin-binding Studies
Scatchard analysis of three binding experiments revealed the
presence oftwo classes of binding sites for CT, one with high
affinity (kD 1 .1 nM) and low capacity (1.5 x 103 sites/cell)
and one with lower affinity (kD 6.6 AM) and higher capacity
(5.6 x 106 sites/cell) (Fig . 9) .
Effects ofSalmon CTon FLG291 Cell Differentiation
Induced by TPA
72-h incubation with 0.1 AM TPA in the presence of 1 nM
salmon CT significantly altered cell adhesion (54 f 8%,
p < 0.02) and multinuclearity (59 ± 10%, p < 0.02) of
FLG 29.1 cells as compared to control cells exposed to TPA
alone (Table II) . In similar experimental conditions also the
2
O
F
a J
U
U
a
a
a u
a
O V r O
w a
0
E n
15
10
0 12 11 10 9 S 7
- Log [sCTJ M
0
CELL TYPE
￿
FLG 29 .1
￿
HL60
￿
U937
Salmon CT (1 nM)
￿
-
￿
+
￿
-
￿
+
￿
-
￿
+
443
Figure 8. Cyclic AMP responses of TPA-treated FLG 29.1 (0),
HL60 (1), and U937 (1) cells to 1 nM salmon CT. Cyclic AMP
was assayed in quadruplicate experimental points as described in
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Figure 9 Equilibrium of [1251]salmon CT binding to differentiated
FLG 29.1 cells. Fitted curve on Scatchard plot was derived from
predicted relationship for two-site model for [1251]salmon CT, as de-
termined by LIGAND program (47).
TRAPase activity (61 f 3 % ofcontrol, p < 0.01), the genera-
tion of oxygen-derived free radicals (42 f 5 % of control,
p < 0.001), and the tPA cell content (75 f 3 % of control,
p < 0.01) of differentiated FLG 29.1 cells were significantly
inhibited by 1 nM salmon CT (Table II) . Treatment of TPA-
induced FLG 29.1 cells with 1 nM salmon CT for 3 h
resulted in a marked cellular contraction measured as the
change in FLG 29.1 plan area by histomorphometry (65 f
8 % ofcontrol; Table II). Similar cellular contraction was ob-
served for mononuclear- and multinucleated-differentiated
FLG 29.1 cells.
Effectsof1,25(OH)ID3 on FLG 29 .1 Cell Differentiation
Treatment of FLG 29.1 cells with 10 nM 1,25(OH)2D3 for
72 h increased up to 15 t 2% the number of adherent cells.
Over 20 t 4% were multinucleated and 15 f 2% became
TRAPase positive. No correlation existed amongadherence,
multinucleation, and expression of TRAPase. In similar ex-
perimental conditions, 1 nM salmon CT significantly in-
creased cAMP accumulation in 1,25(OH)2D3-induced FLG
29.1 cells (181 f 25% of control, p < 0.02). Conversely,
FACS and APAAP analyses did not evidence induction ofthe
two antigens recognized by the mAbs 13C2 and 23C6 in
1,25(OH)2D3-induced FLG 29.1 cells. Moreover no differ-
TableII. Effects of 1 nM Salmon CT on
FLG 29.1 Cell Differentiation Induced by
T2-hour Treatment with 0.1 AM TPA
* Salmon CT (1 nM) was incubated with the cells during the entire 72-h TPA
treatment.
~ Salmon CT (1 nM)was added for 3 hat the end of the 72-h TPA treatment.
§ Results are expressed as mean t SD.
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ences were observed in the expression of the above antigens
between FLG 29.1 cells treated with 0.1 p,M TPA alone or
with 0.1 wM TPA and 10 nM 1,25(OH)2D3 for 72 h (data
not shown).
Discussion
Extensive cytological descriptions ofthe osteoclast exist, but
there is little known about the mechanisms and the kinetics
ofprogression from inactive or immature progenitor cells to
actively resorbing elements. In fact, suitable markers for
identifying osteoclast progenitor cellsto terminally differen-
tiated elements is still missing. Hormones, growth factors,
interactions with bone cells of different nature, as well as
with organic and inorganic substrata, seem to influence the
differentiation and activation processes.
Originally, mononuclear phagocytes were considered to
be osteoclast precursors on the basis of their morphological
and enzymatic properties as well as their capacity to form
multinucleated giant cells (65), but it was concluded later
that macrophages per se were not identifiable as the precur-
sor cellsof terminally differentiated osteoclasts. In fact, evi-
dence from the fetal bone rudiment co-culture and the os-
teopetrotic transplant models demonstrated that osteoclasts
are not formed by the fusion of mature monocytes and mac-
rophages, indicating that the osteoclast progenitor is a
pluripotent hemopoietic stem cell (12, 61) . Moreover, mac-
rophages are distinct in phenotype and immunotype (29, 30)
and lack calcitonin responsiveness (15, 48). On the other
hand, Udagawa and co-workers reported that osteoclastic
cells may also be derived from mature monocytes and mac-
rophages in contact with bone marrow-derived stromal cells
(71) . This suggested that monocytic cells may also give rise
to osteoclasts under the influence of local bone factors plus
systemic hormones such as 1,25(OH)2D3 and dexametha-
sone (71) . Given these conflicting findings, the availability of
a clonal cell line of progenitor cells able to differentiate
into osteoclast-like elements under appropriate stimulation,
might be ofgreat advantage in understanding the pathophys-
iology ofosteoclasts and their relationships with other bone-
derivedcells. Here wedescribe theestablishment andcharac-
terization ofa cloned leukemic cell line ofputative osteoclast
progenitors. Interestingly, the patient from which primary
cultures were obtained, suffered in the terminal phase of her
illness from an osteopetrosis-like syndrome. This latter find-
ing could be the result of a deficient productionof mature os-
teoclasts because of the neoplastic transformation of their
progenitors and leading to an unbalanced bone formation by
osteoblasts. This situation closely reminds the lack of the
mature neutrophil which accompanies the neoplastic trans-
formation ofmyelopoietic progenitors in acute myeloid leu-
kemia. Our biological characterization of FLG 29.1 overall
indicates that these cells may actually represent osteoclast
progenitors.
The composite pattern of membrane antigen expression of
differentiated FLG 29.1 cells is very similar to the surface
phenotype of fetalbone osteoclasts: reactivitywith the CD9,
CD13, CD32, and CD42b mAbs, strong reactivity with two
mAbs 23C6 (CD51/VNR« chain), and 13C2 originally de-
scribed as osteoclast-specific markers (30), along with the
presence of a restricted number of cell adhesion molecules
(ICAM-1/CD54, H-CAM/CD44, and CD61/gpHIa/VNRß
chain) and of the leukocyte common antigen CD45 (3, 5, 6,
44
+ salmon CT
(Percent of control)§ p
Adhesion 54 t 8* <0.02
Multinuclearity 59 t 10* <0.02
TRAPase activity 61 t 3* <0.01
NBT 42 t 5* <0.001
tPA 75 t 3* <0.01
Plan area 65 t 8$ <0.0130, 31). The CDllb (Mol) determinant, found on immature
precursors but not on mature osteoclasts (46), is expressed
in TPAtreated FLG 29.1 cells. The existence of CD31 (gp
Ha) in FLG 29.1 cellsis the only discrepancy foundbetween
osteoclastic and FLG 29.1 cell antigens. Moreover, even
though the few published studies find no CD31 expression
on mature osteoclast (6, 31), a systematic survey ofgpHa ex-
pression in immature osteoclasts or osteoclast precursors has
not been performed to date. Therefore, CD31 expression at
specific stages of osteoclastic differentiation cannot be ex-
cluded. The lack of detectable CD14, CD33, CD4, CD35,
CD36, CDlla (LFA-1), CD25, and MHC class II (HLA-DR)
molecules characterizes FLG 29.1 as distinct from mono-
cyte-macrophage cell types or macrophage polykaria (6) .
Similarly, the lack of CD41 (IIb-IIIa) and of factor VIII-re-
lated antigen further differentiates the FLG 29.1 cell from
megakaryocytes. Note that the only macrophage-specific de-
terminant CD68, intracytoplasmatically expressed by FLG
29.1 cells, also has been found recently on bone osteoclasts
(4, 6). Finally, using Kn22, a unique n Ab that identifies an
osteoclast precursor, we were able to detect the 50 kD anti-
gen, a membrane protein present on pre-osteoclasts and ma-
ture osteoclasts (35), in TPA-treated FLG 29.1 cells, while
undifferentiated cells were negative. Taken together, these
data suggest that the overall immunophenotype ofTPAtreated
FLG 29.1 cells is fullycompatible with that of cells differen-
tiating along the osteoclast-like lineage.
Further evidence of the similarity between differentiated
FLG 29.1 and osteoclast-like cells include multinuclearity,
TRAPase-positivity, capacity for resorbing mineral from
bone fragments, and calcitonin responsiveness. Only the lat-
ter feature, however, is considered a reliable and early
marker for osteoclastic differentiation in vitro, being absent
in cellsofthe mononuclear phagocyte lineage (25); the other
functions are foundin macrophages as well (23, 26) . Indeed,
CT receptors were shown to identify mononuclear cells
committed to the osteoclast lineage and are expressed before
the acquisition of bone resorptive capacity by osteoclasts
(25, 37) . Calcitonin treatment of differentiated FLG 29.1
cells was also associated with cellular contraction, as previ-
ously shown in mature osteoclasts (49). Accordingly, incu-
bation with CT during the differentiative period induced
reduction of cell adherence, of multinuclearity, and of ex-
pression of several enzymatic activities. These findings to-
gether with the demonstration of specific binding sites for
CT in differentiated FLG 29.1 cells clearly demonstrate a
specific biological function of the hormone in this cell line.
Differently than expression of CT receptors, TRAPase, and
multinuclearity are reliable markers for osteoclastic pheno-
type in bone, but they are unreliable markers in culture (26) .
And these conclusions are further supported by the lack of
correlation of several of the osteoclastic features of differen-
tiated FLG 29.1 cells with multinuclearity. Ultrastructural
studies also revealed differentiation of FLG 29.1 cells to-
wards osteoclast-like cells (22, 42) . The FLG 29.1 cells in-
deed acquire in culture some ultrastructural features of
osteoclast-like cells (22, 42).
Under the culture conditions used in these experiments,
FLG 29.1 cells express only some osteoclastic features. The
differentiative agentusedin these studies, TPA, is nonspecific
and known to prime other leukemic cell lines towards the
macrophagic phenotype (59). Interestingly, Su and co-work-
ers have recently shown that activation of protein kinase C
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inhibits bone resorption in rat osteoclasts (64). Therefore, it
is possible that under other culture conditions, fully devel-
oped osteoclasts may form from undifferentiated FLG 29.1
cells. In this regard, Kukita and colleagues (36) suggest that
interaction of osteoclasts with bone matrix could influence
cell differentiation. It is well known that osteoblasts are criti-
cal for hormonally controlled osteoclastic bone resorption
(16, 44, 57). Moreover, marrow-derived stromal cells can
support osteoclastic cell differentiation in co-culture with
spleen cells (70). Finally, one notes that existing in vitro
models of osteoclastic resorption represent mixed cell cul-
tures, true osteoclasts accounting for only a fraction of the
total cell population.
It is of interest to note that the steroid hormone
1,25(OH)2D3, known to control the differentiation of myelo-
monocytic precursors toward the macrophage and/or osteo-
clastlineages (1, 2, 7, 27, 54, 58, 68), acts as weak inducer
on FLG 29.1 cells. A number of lines of evidence might
justify this lack of hormonal responsiveness. First, in the
currently accepted osteoclast differentiation scheme sensi-
tivity to 1,25(OH)2D3 appears at a late pre-osteoclast stage
(46, 67). It is, therefore, conceivable that undifferentiated
FLG 29.1 cells being arrested at an earlier maturation step
are not sensitive to the action of 1,25(OH)2D3 . Second,
1,25(OH)2D3 induces an increase in bone resorption in vivo
(7), in organ culture (27, 54), and in long-term bone marrow
cultures (58, 68), but has no effect on the resorptive activity
of isolated osteoclasts (18, 20) . Thken together, these results
suggest that a clonal cell population, like FLG 29.1 is, may
not be suitable for demonstrating the differentiative action of
1,25(OH)2D3 toward the osteoclast lineage, because of the
absence of other cell types that may influence the response
to the hormone (i.e., osteoblasts and/or stromal cells) .
We report here the development of a human leukemic cell
line that, upon treatment with TPA acquires some functional
and antigenic properties ofmature osteoclasts, albeit further
stimulation might be required to develop the whole func-
tional repertoire of terminally differentiated osteoclasts,
such as cavitating bone resorption. This model should yield
detailed identification of many of the steps and mechanisms
controlling them, for differentiating toward osteoclasts.
Moreover, further experiments manipulating the cell envi-
ronment may lead to elucidation of the complete pathway for
osteoclast development from precursors.
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